In line with its patient-first approach, Sri Lanka Chamber of the Pharmaceutical Industry
(SLCPI), which represents over 60 major importers of pharmaceuticals, accounting for 85% of Sri
Lanka’s medicines market, has reiterated the support and commitment of its members towards working
with the authorities in addressing the COVID-19 current situation by ensuring continuity of supply of
medicines. “SLCPI and its member companies reassure the availability of adequate supplies of medicines
for those in need of them” quoted a statement to media.
.
While thanking consumers for being responsible in their purchasing of prescription drugs, SLCPI assured
the general public that inventory of adequate stocks will sustain the supply and availability of medicines
and not create any shortages, particularly with the current outbreak.
SLCPI also noted that they are working with relevant stakeholders to ensure an uninterrupted supply
chain, while dismissing fears of possible shortages, as unnecessary and creating undue panic.
“The orders placed with our manufacturing partners and principals in India and other Countries are
being fulfilled and we will ensure that our consumers will continue to have access to quality medicines,
seamlessly. Our membership is closely monitoring orders and inventories,” the statement re-iterated,
adding that the needs of the public are priority, especially those in the non-communicable diseases
(NCDs) segment.
“SLCPI members are committed to working on measures to ensure that there are no shortages and that
there is continuity in the pharmaceutical supply chain through focused engagement with all critical
stakeholders and supply chains, including the principals, worldwide”.
“We will ensure that access to medicines will continue for those that need them and urge the public to
be sensible and judicious in their reaction to the current situation.”
About SLCPI
The SLCPI currently serves as the representative of over 60 members who account for more than 85%
of the private pharmaceutical industry, spanning manufacturers, importers, distributors and retailers.
These stakeholders supply Sri Lankan patients with 800 molecules from 364 manufacturers from across
the world.
